Throughout the world, more than 600,000 woman are being diagnosed annually with cervical cancer that is caused by human papillomavirus (HPV)¹⁾. However, the risk of cervical cancer can be predicted and prevented if high-risk HPV types are detected in early stages with regular screening.
WHO recommends DNA testing for primary cervical cancer screening¹⁾ and the recent trends show that screening method is shifting from the cytology test to HPV DNA test. Furthermore, the prevalence of HPV type is different across the world due to increasing vaccination and difference in regional characteristics²⁾, leading DNA testing more useful in screening HPVs.
Allplex™ HPV HR Detection is a multiplex real-time PCR assay that enables simultaneous amplification and detection of target nucleic acids of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) as well as Internal Control (IC).